Search

Your search keyword '"Sergii Shevnya"' showing total 5 results
Start Over Author "Sergii Shevnya"
5 results on '"Sergii Shevnya"'

1. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Author

Luis, Fein, Gonzalo, Gomez Abuin, Diego, Kaen, Ruben, Kowalwszyn, Matias, Molina, Mirta, Varela, Sally, Baron-Hay, Stephen, Begbie, Philip, Clingan, Sherene, Loi, Dhanusha, Sabanathan, Andrea, Gombos, Donatienne, Taylor, Carlos, Barrios, Leandro, Brust, Fabiano, Costa, Ruffo, de Freitas Junior, Roberto, Hegg, Domicio Carvalho, Lacerda, Fernando Cezar Toniazzi, Lissa, Roberto Odebrecht, Rocha, Antonio Orlando, Scalabrini Neto, Felipe, Silva, David, Cescon, Danielle, Charpentier, Cristiano, Ferrario, Xinni, Song, Joanne, Yu, Alejandro, Acevedo, Carlos, Gallardo, Claudio, Salas, Cesar, Sanchez, Eduardo, Yanez, Alvaro, Gomez Diaz, Jesus, Sanchez, Petra, Holeckova, Zdenek, Kral, Bohuslav, Melichar, Katarina, Petrakova, Jana, Prausova, Vesna, Glavicic, Erik, Jakobsen, Jeanette, Jensen, Soren, Linnet, Tamas, Lorincz, Herve, Bonnefoi, Isabelle, Desmoulins, Anthony, Goncalves, Anne-Claire, Hardy-Bessard, Luis, Teixeira, Jens-Uwe, Blohmer, Peter, Fasching, Dirk, Forstmeyer, Nadia, Harbeck, Jens, Huober, Anna, Kaczerowsky Flores de Sousa, Christian, Kurbacher, Sibylle, Loibl, Diana, Lueftner, Tjoung-Won, Park-Simon, Raquel Von, Schumann, Pauline, Wimberger, Louis, Chow, Ava, Kwong, Kai Cheong Roger, Ngan, Peter, Arkosy, Tibor, Csoszi, Zsuzsanna, Kahan, Laszlo, Landherr, Karoly, Mahr, Gabor, Rubovszky, John, Crown, Catherine, Kelly, Seamus, O'Reilly, Saverio, Cinieri, Antonietta, DAlessio, Enrico, Ricevuto, Tomoyuki, Aruga, Takaaki, Fujii, Kenichi, Inoue, Takashi, Ishikawa, Yoshinori, Ito, Tsutomu, Iwasa, Hiroji, Iwata, Yoshimasa, Kosaka, Koji, Matsumoto, Yasuo, Miyoshi, Hirofumi, Mukai, Seigo, Nakamura, Naoki, Niikura, Shoichiro, Ohtani, Akihiko, Osaki, Yasuaki, Sagara, Eiji, Suzuki, Masato, Takahashi, Yuko, Tanabe, Kenji, Tamura, Koichiro, Tsugawa, Junichiro, Watanabe, Naohito, Yamamoto, Yutaka, Yamamoto, Teruo, Yamauchi, Anita, Bustam, Mastura, Md Yusof, Angel, Gomez Villanueva, Alejandro, Juarez Ramiro, Jorge, Martinez Rodriguez, Flavia, Morales-Vasquez, Jessica, Reyes Contreras, Karin, Beelen, Vivianne, Tjan-Heijnen, David, Porter, Ewa, Chmielowska, Ewa, Nowakowska-Zajdel, Zbigniew, Nowecki, Barbara, Radecka, Joanna, Streb, Cezary, Szczylik, Rafal, Tarnawski, Bogdan, Zurawski, Alexander, Arkhipov, Natalia, Fadeeva, Oleg, Lipatov, Andrey, Meshcheryakov, Vladimir, Moiseyenko, Guzel, Mukhametshina, Jin Hee, Ahn, Seock-Ah, Im, Keun Seok, Lee, Kwong Hwa, Park, Yeon Hee, Park, Begona, Bermejo de las Heras, Javier, Cortes, Josefina, Cruz Jurado, Luis, de la Cruz Merino, Jose, Garcia Saenz, Maria, Gion, Esther, Holgado, Esther, Zamora Adelantado, Chien-Ting, Liu, Mei-Ching, Liu, Chiun-Sheng, Huang, Chao-Jung, Tsao, Ling-Ming, Tseng, Cagatay, Arslan, Gul, Basaran, Irfan, Cicin, Erhan, Gokmen, Seyda, Gunduz, Nil, Molinas Mandel, Mustafa, Ozguroglu, Ozgur, Ozyilkan, Sinan, Yavuz, Steve, Chan, Janine, Graham, Iain, MacPherson, Peter, Schmid, Nicholas, Turner, Mark, Tuthill, Christopher, Twelves, Duncan, Wheatley, Hryhoriy, Adamchuk, Oleksandr, Berzoy, Igor, Bondarenko, Oleksii, Kolesnik, Olena, Kolesnik, Hanna, Komisarenko, Anna, Kryzhanivska, Iurii, Leshchenko, Alla, Nasonova, Natalya, Otchenash, Olga, Ponomarova, Andrii, Rusyn, Sergii, Shevnya, Yaroslav, Shparyk, Dmytro, Trukhin, Grygorii, Ursol, Ihor, Vynnychenko, Sibel, Blau, Madhu, Chaudhry, Michael, Chung, Patrick, Cobb, Scott, Cole, Jennifer, Diamond, Keerthi, Gogineni, Jeffrey, Hargis, Kent, Hoskins, William, Irvin, Randa, Loutfi, Janice, Lu, Raul, Mena, Susan, Moore, Rita, Nanda, Ira, Oliff, Coral, Omene, Timothy, Panella, Amit, Panwalkar, Brian, Patson, Hope, Rugo, Irina, Rybalova, Michael, Schleider, Robert, Siegel, Michael, Simon, Laura, Stampleman, Bradley, Sumrall, Michaela, Tsai, Frances, Valdes-Albini, Cortes, Javier, Cescon, David W, Rugo, Hope S, Nowecki, Zbigniew, Im, Seock-Ah, Yusof, Mastura Md, Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H, Holgado, Esther, Iwata, Hiroji, Masuda, Norikazu, Otero, Marco Torregroza, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhao, Jing, Aktan, Gursel, Karantza, Vassiliki, and Schmid, Peter

Published
2020
Full Text
View/download PDF

2. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

Author

Claire Verschraegen, Zoran Andric, Fedor Moiseenko, Tamta Makharadze, Sergii Shevnya, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Sijin Park, Hana Ju, and Yuichiro Ohe

Subjects
Pharmacology, Lung Neoplasms, General Medicine, Bevacizumab, Double-Blind Method, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Humans, Pharmacology (medical), European Union, Neoplasm Recurrence, Local, Tomography, X-Ray Computed, Biosimilar Pharmaceuticals, Biotechnology
Abstract

CT-P16 is a candidate bevacizumab biosimilar.This double-blind, multicenter, parallel-group, phase III study aimed to establish equivalent efficacy between CT-P16 and European Union-approved reference bevacizumab (EU-bevacizumab) in patients with metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC).Patients with stage IV or recurrent nsNSCLC were randomized (1:1) to receive CT-P16 or EU-bevacizumab (15 mg/kg every 3 weeks; ≤ 6 cycles) with paclitaxel (200 mg/mOverall, 689 patients were randomized (CT-P16, N = 342; EU-bevacizumab, N = 347). ORR was 42.40% (95% confidence interval [CI] 37.16-47.64) and 42.07% (95% CI 36.88-47.27) for CT-P16 and EU-bevacizumab, respectively. The risk difference (0.40 [95% CI - 7.02 to 7.83]) and risk ratio (1.0136 [90% CI 0.8767-1.1719]) for ORR fell within predefined equivalence margins (- 12.5 to + 12.5%, and 0.7368 to 1.3572, respectively), demonstrating equivalence between CT-P16 and EU-bevacizumab. Median response duration, time to progression, progression-free survival, and overall survival were comparable between treatment groups. Safety profiles were similar: 96.2% (CT-P16) and 93.0% (EU-bevacizumab) of patients experienced treatment-emergent adverse events. Pharmacokinetics and immunogenicity were comparable between groups.Equivalent efficacy and similar pharmacokinetics, safety, and immunogenicity support bioequivalence of CT-P16 and EU-bevacizumab in patients with nsNSCLC.NCT03676192.

Published
2022
Full Text
View/download PDF

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Author

Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko, Kaoru Kubota, Gregory M Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes, Grigory Adamchuk, Myung-Ju Ahn, Aurelia Alexandru, Ozden Altundag, Anna Alyasova, Orest Andrusenko, Keisuke Aoe, Antonio Araujo, Osvaldo Aren, Oscar Arrieta Rodriguez, Touch Ativitavas, Oscar Avendano, Fernando Barata, Carlos Henrique Barrios, Carlos Beato, Per Bergstrom, Daniel Betticher, Larisa Bolotina, Michiel Botha, Sayeuri Buddu, Christian Caglevic, Andres Cardona, Hugo Castro, Filiz Cay Senler, Carlos Alexandre Sydow Cerny, Alvydas Cesas, Gee-Chen Chan, Jianhua Chang, Gongyan Chen, Xi Chen, Susanna Cheng, Ying Cheng, Nelly Cherciu, Chao-Hua Chiu, Saulius Cicenas, Daniel Ciurescu, Graham Cohen, Marcos Andre Costa, Pongwut Danchaivijitr, Flavia De Angelis, Sergio Jobim de Azevedo, Mircea Dediu, Tsvetan Deliverski, Pedro Rafael Martins De Marchi, Flor de The Bustamante Valles, Zhenyu Ding, Boyan Doganov, Lydia Dreosti, Ricardo Duarte, Regina Edusma-Dy, Sergey Emelyanov, Mustafa Erman, Yun Fan, Luis Fein, Jifeng Feng, David Fenton, Gustavo Fernandes, Carlos Ferreira, Fabio Andre Franke, Helano Freitas, Yasuhito Fujisaka, Hector Galindo, Christina Galvez, Doina Ganea, Nuno Gil, Gustavo Girotto, Erdem Goker, Tuncay Goksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, Hakan Griph, Mahmut Gumus, Jacqueline Hall, Gregory Hart, Libor Havel, Jianxing He, Yong He, Carlos Hernandez Hernandez, Venceslau Hespanhol, Tomonori Hirashima, Chung Man James Ho, Atsushi Horiike, Yukio Hosomi, Katsuyuki Hotta, Mei Hou, Soon Hin How, Te-Chun Hsia, Yi Hu, Masao Ichiki, Fumio Imamura, Oleksandr Ivashchuk, Yasuo Iwamoto, Jana Jaal, Jacek Jassem, Christa Jordaan, Rosalyn Anne Juergens, Diego Kaen, Ewa Kalinka-Warzocha, Nina Karaseva, Boguslawa Karaszewska, Andrzej Kazarnowicz, Kazuo Kasahara, Nobuyuki Katakami, Terufumi Kato, Tomoya Kawaguchi, Joo Hang Kim, Kazuma Kishi, Vitezslav Kolek, Marchela Koleva, Petr Kolman, Leona Koubkova, Ruben Kowalyszyn, Dariusz Kowalski, Krassimir Koynov, Doran Ksienski, Takayasu Kurata, Gerli Kuusk, Lyudmila Kuzina, Ibolya Laczo, Guia Elena Imelda Ladrera, Konstantin Laktionov, Gregory Landers, Sergey Lazarev, Guillermo Lerzo, Krzysztof Lesniewski Kmak, Wei Li, Chong Kin Liam, Igor Lifirenko, Oleg Lipatov, Xiaoqing Liu, Zhe Liu, Sing Hung Lo, Valeria Lopes, Karla Lopez, Shun Lu, Gaston Martinengo, Luis Mas, Marina Matrosova, Rumyana Micheva, Zhasmina Milanova, Lucian Miron, Tony Mok, Matias Molina, Shuji Murakami, Yasuharu Nakahara, Tien Quang Nguyen, Takashi Nishimura, Adrian Ochsenbein, Tatsuo Ohira, Ronny Ohman, Choo Khoon Ong, Gyula Ostoros, Xuenong Ouyang, Elena Ovchinnikova, Ozgur Ozyilkan, Lubos Petruzelka, Xuan Dung Pham, Pablo Picon, Bela Piko, Artem Poltoratsky, Olga Ponomarova, Patrice Popelkova, Gunta Purkalne, Shukui Qin, Rodryg Ramlau, Bernardo Rappaport, Felipe Rey, Eduardo Richardet, Jaromir Roubec, Paul Ruff, Andrii Rusyn, Hideo Saka, Jorge Salas, Mario Sandoval, Lucas Santos, Toshiyuki Sawa, Kasan Seetalarom, Mesut Seker, Nobuhiko Seki, Freddy Seolwane, Lucinda Shepherd, Sergii Shevnya, Andrea Kazumi Shimada, Yaroslav Shparyk, Ivan Sinielnikov, Daniela Sirbu, Oren Smaletz, Joao Paulo Holanda Soares, Aumkhae Sookprasert, Giovanna Speranza, Virote Sriuranpong, Zinaida Stara, Wu-Chou Su, Shunichi Sugawara, Waldemar Szpak, Kazuhisa Takahashi, Nagio Takigawa, Hiroshi Tanaka, Jerry Tan Chun Bing, Qiyou Tang, Pavel Taranov, Hermes Tejada, Lye Mun Tho, Yoshitaro Torii, Dmytro Trukhyn, Maria Turdean, Hande Turna, Grygoriy Ursol, Jaroslav Vanasek, Mirta Varela, Marcela Vallejo, Luis Vera, Ana-Paula Victorino, Tomas Vlasek, Ihor Vynnychenko, Buhai Wang, Jie Wang, Kai Wang, Yilong Wu, Kazuhiko Yamada, Chih-Hsin Yang, Takuma Yokoyama, Toshihide Yokoyama, Hiroshige Yoshioka, Fulden Yumuk, Angela Zambrano, Juan Jose Zarba, Oleg Zarubenkov, Marius Zemaitis, Li Zhang, Xin Zhang, Jun Zhao, Caicun Zhou, Jianying Zhou, Qing Zhou, and Alfred Zippelius

Subjects
medicine.medical_specialty, Chemotherapy, education.field_of_study, Performance status, business.industry, medicine.medical_treatment, Hazard ratio, Population, Phases of clinical research, General Medicine, Pembrolizumab, 030204 cardiovascular system & hematology, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Carcinoma, 030212 general & internal medicine, business, Lung cancer, education
Abstract

Background First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater. Methods This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater. Randomisation was computer generated, accessed via an interactive voice-response and integrated web-response system, and stratified by region of enrolment (east Asia vs rest of world), ECOG performance status score (0 vs 1), histology (squamous vs non-squamous), and PD-L1 TPS (≥50% vs 1-49%). Enrolled patients were randomly assigned 1:1 in blocks of four per stratum to receive pembrolizumab 200 mg every 3 weeks for up to 35 cycles or the investigator's choice of platinum-based chemotherapy for four to six cycles. Primary endpoints were overall survival in patients with a TPS of 50% or greater, 20% or greater, and 1% or greater (one-sided significance thresholds, p=0·0122, p=0·0120, and p=0·0124, respectively) in the intention-to-treat population, assessed sequentially if the previous findings were significant. This study is registered at ClinicalTrials.gov, number NCT02220894. Findings From Dec 19, 2014, to March 6, 2017, 1274 patients (902 men, 372 women, median age 63 years [IQR 57-69]) with a PD-L1 TPS of 1% or greater were allocated to pembrolizumab (n=637) or chemotherapy (n=637) and included in the intention-to-treat population. 599 (47%) had a TPS of 50% or greater and 818 patients (64%) had a TPS of 20% or greater. As of Feb 26, 2018, median follow-up was 12·8 months. Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations (≥50% hazard ratio 0·69, 95% CI 0·56-0·85, p=0·0003; ≥20% 0·77, 0·64-0·92, p=0·0020, and ≥1% 0·81, 0·71-0·93, p=0·0018). The median surival values by TPS population were 20·0 months (95% CI 15·4-24·9) for pembrolizumab versus 12·2 months (10·4-14·2) for chemotherapy, 17·7 months (15·3-22·1) versus 13·0 months (11·6-15·3), and 16·7 months (13·9-19·7) versus 12·1 months (11·3-13·3), respectively. Treatment-related adverse events of grade 3 or worse occurred in 113 (18%) of 636 treated patients in the pembrolizumab group and in 252 (41%) of 615 in the chemotherapy group and led to death in 13 (2%) and 14 (2%) patients, respectively. Interpretation The benefit-to-risk profile suggests that pembrolizumab monotherapy can be extended as first-line therapy to patients with locally advanced or metastatic non-small-cell lung cancer without sensitising EGFR or ALK alterations and with low PD-L1 TPS. Funding Merck Sharp & Dohme.

Published
2019
Full Text
View/download PDF

4. Abstract CT551: Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin®) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)

Author

Yuichiro Ohe, Igor Bondarenko, Zoran Andric, Yuriy Ostapenko, Tudor Ciuleanu, Fedor Moiseenko, Tamta Makharadze, Sergii Shevnya, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Sijin Park, JiEun Lee, MinJi Kim, and Claire Verschraegen

Subjects
Cancer Research, Oncology
Abstract

Background: CT-P16 is a proposed biosimilar to FDA approved reference bevacizumab (BV), namely Avastin®. This trial (NCT03676192) compared the efficacy and safety of CT-P16 and BV in patients with metastatic or recurrent non-squamous NSCLC. Methods: This double blind, randomized, multicenter study randomly assigned patients to CT-P16 or BV with carboplatin and paclitaxel, up to 6 cycles (Induction Period), followed by maintenance CT-P16 or BV monotherapy until disease progression or intolerable toxicity. The primary endpoint was objective response rate (ORR) during the Induction Period. ORR includes complete or partial responses based on RECIST v1.1 assessed by an independent reviewer. Secondary endpoints were Quality of life (QoL), PK, safety, and immunogenicity. Results: A total of 689 patients were randomized (CT-P16: 342, BV: 347). The baseline characteristics were well balanced. ORRs were similar between the two treatment arms and the 90% confidence intervals (CIs) for the risk ratio estimate (0.7368, 1.3572) and 95% CIs for risk difference estimate (±12.5%) were within the equivalence margin in both ITT (intent-to-treat) and PP (per-protocol) sets. QoL results (QLQ-C30 and QLQ-LC13) and PK parameter (Ctrough) were comparable between the two treatment arms. The overall incidence of treatment-emergent adverse events (TEAEs), serious AEs (TESAEs), AEs leading to discontinuation, and AEs leading to death was similar between the two treatment arms (96.2% vs. 92.4%, 19.4% vs. 20.1%, 15.1% vs. 14.5%, and 6.4% vs. 6.4% for the CT-P16 and BV treatment arm, respectively). The incidence of treatment-emergent anti-drug antibodies was comparable (14.2% vs. 16.0%). Conclusions: This study demonstrated that CT-P16 is equivalent to BV as measured by ORR in patients with metastatic or recurrent adenocarcinoma of the lung. Other endpoints including PK, QoL, safety and immunogenicity were comparable. Primary endpoint ITT PP CT-P16 (N=342) BV (N=347) CT-P16 (N=318) BV (N=303) Independent reviewer ORR (%) 95% CI 42.40 (37.16 - 47.64) 42.07 (36.88 - 47.27) 45.28 (39.81 - 50.75) 47.19 (41.57 - 52.82) Risk ratio estimate (90% CI) 1.0136 (0.8767, 1.1719) 0.9662 (0.8387, 1.1132) Risk difference estimate (%) (95% CI) 0.40 (-7.02, 7.83) -1.90 (-9.80, 6.00) Investigator ORR (%) 95% CI 43.86 (38.60 - 49.12) 39.19 (34.06 - 44.33) 46.54 (41.06 - 52.02) 43.89 (38.31 - 49.48) Risk ratio estimate (90% CI) 1.1234 (0.9683, 1.3032) 1.0648 (0.9209, 1.2313) Risk difference estimate (%) (95% CI) 4.87 (-2.53, 12.26) 2.90 (-4.99, 10.79) Citation Format: Yuichiro Ohe, Igor Bondarenko, Zoran Andric, Yuriy Ostapenko, Tudor Ciuleanu, Fedor Moiseenko, Tamta Makharadze, Sergii Shevnya, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Sijin Park, JiEun Lee, MinJi Kim, Claire Verschraegen. Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin®) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT551.

Published
2022
Full Text
View/download PDF

5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Author

Cortes, Javier, primary, Cescon, David W, additional, Rugo, Hope S, additional, Nowecki, Zbigniew, additional, Im, Seock-Ah, additional, Yusof, Mastura Md, additional, Gallardo, Carlos, additional, Lipatov, Oleg, additional, Barrios, Carlos H, additional, Holgado, Esther, additional, Iwata, Hiroji, additional, Masuda, Norikazu, additional, Otero, Marco Torregroza, additional, Gokmen, Erhan, additional, Loi, Sherene, additional, Guo, Zifang, additional, Zhao, Jing, additional, Aktan, Gursel, additional, Karantza, Vassiliki, additional, Schmid, Peter, additional, Luis, Fein, additional, Gonzalo, Gomez Abuin, additional, Diego, Kaen, additional, Ruben, Kowalwszyn, additional, Matias, Molina, additional, Mirta, Varela, additional, Sally, Baron-Hay, additional, Stephen, Begbie, additional, Philip, Clingan, additional, Sherene, Loi, additional, Dhanusha, Sabanathan, additional, Andrea, Gombos, additional, Donatienne, Taylor, additional, Carlos, Barrios, additional, Leandro, Brust, additional, Fabiano, Costa, additional, Ruffo, de Freitas Junior, additional, Roberto, Hegg, additional, Domicio Carvalho, Lacerda, additional, Fernando Cezar Toniazzi, Lissa, additional, Roberto Odebrecht, Rocha, additional, Antonio Orlando, Scalabrini Neto, additional, Felipe, Silva, additional, David, Cescon, additional, Danielle, Charpentier, additional, Cristiano, Ferrario, additional, Xinni, Song, additional, Joanne, Yu, additional, Alejandro, Acevedo, additional, Carlos, Gallardo, additional, Claudio, Salas, additional, Cesar, Sanchez, additional, Eduardo, Yanez, additional, Alvaro, Gomez Diaz, additional, Jesus, Sanchez, additional, Petra, Holeckova, additional, Zdenek, Kral, additional, Bohuslav, Melichar, additional, Katarina, Petrakova, additional, Jana, Prausova, additional, Vesna, Glavicic, additional, Erik, Jakobsen, additional, Jeanette, Jensen, additional, Soren, Linnet, additional, Tamas, Lorincz, additional, Herve, Bonnefoi, additional, Isabelle, Desmoulins, additional, Anthony, Goncalves, additional, Anne-Claire, Hardy-Bessard, additional, Luis, Teixeira, additional, Jens-Uwe, Blohmer, additional, Peter, Fasching, additional, Dirk, Forstmeyer, additional, Nadia, Harbeck, additional, Jens, Huober, additional, Anna, Kaczerowsky Flores de Sousa, additional, Christian, Kurbacher, additional, Sibylle, Loibl, additional, Diana, Lueftner, additional, Tjoung-Won, Park-Simon, additional, Raquel Von, Schumann, additional, Pauline, Wimberger, additional, Louis, Chow, additional, Ava, Kwong, additional, Kai Cheong Roger, Ngan, additional, Peter, Arkosy, additional, Tibor, Csoszi, additional, Zsuzsanna, Kahan, additional, Laszlo, Landherr, additional, Karoly, Mahr, additional, Gabor, Rubovszky, additional, John, Crown, additional, Catherine, Kelly, additional, Seamus, O'Reilly, additional, Saverio, Cinieri, additional, Antonietta, DAlessio, additional, Enrico, Ricevuto, additional, Tomoyuki, Aruga, additional, Takaaki, Fujii, additional, Kenichi, Inoue, additional, Takashi, Ishikawa, additional, Yoshinori, Ito, additional, Tsutomu, Iwasa, additional, Hiroji, Iwata, additional, Yoshimasa, Kosaka, additional, Koji, Matsumoto, additional, Yasuo, Miyoshi, additional, Hirofumi, Mukai, additional, Seigo, Nakamura, additional, Naoki, Niikura, additional, Shoichiro, Ohtani, additional, Akihiko, Osaki, additional, Yasuaki, Sagara, additional, Eiji, Suzuki, additional, Masato, Takahashi, additional, Yuko, Tanabe, additional, Kenji, Tamura, additional, Koichiro, Tsugawa, additional, Junichiro, Watanabe, additional, Naohito, Yamamoto, additional, Yutaka, Yamamoto, additional, Teruo, Yamauchi, additional, Anita, Bustam, additional, Mastura, Md Yusof, additional, Angel, Gomez Villanueva, additional, Alejandro, Juarez Ramiro, additional, Jorge, Martinez Rodriguez, additional, Flavia, Morales-Vasquez, additional, Jessica, Reyes Contreras, additional, Karin, Beelen, additional, Vivianne, Tjan-Heijnen, additional, David, Porter, additional, Ewa, Chmielowska, additional, Ewa, Nowakowska-Zajdel, additional, Zbigniew, Nowecki, additional, Barbara, Radecka, additional, Joanna, Streb, additional, Cezary, Szczylik, additional, Rafal, Tarnawski, additional, Bogdan, Zurawski, additional, Alexander, Arkhipov, additional, Natalia, Fadeeva, additional, Oleg, Lipatov, additional, Andrey, Meshcheryakov, additional, Vladimir, Moiseyenko, additional, Guzel, Mukhametshina, additional, Jin Hee, Ahn, additional, Seock-Ah, Im, additional, Keun Seok, Lee, additional, Kwong Hwa, Park, additional, Yeon Hee, Park, additional, Begona, Bermejo de las Heras, additional, Javier, Cortes, additional, Josefina, Cruz Jurado, additional, Luis, de la Cruz Merino, additional, Jose, Garcia Saenz, additional, Maria, Gion, additional, Esther, Holgado, additional, Esther, Zamora Adelantado, additional, Chien-Ting, Liu, additional, Mei-Ching, Liu, additional, Chiun-Sheng, Huang, additional, Chao-Jung, Tsao, additional, Ling-Ming, Tseng, additional, Cagatay, Arslan, additional, Gul, Basaran, additional, Irfan, Cicin, additional, Erhan, Gokmen, additional, Seyda, Gunduz, additional, Nil, Molinas Mandel, additional, Mustafa, Ozguroglu, additional, Ozgur, Ozyilkan, additional, Sinan, Yavuz, additional, Steve, Chan, additional, Janine, Graham, additional, Iain, MacPherson, additional, Peter, Schmid, additional, Nicholas, Turner, additional, Mark, Tuthill, additional, Christopher, Twelves, additional, Duncan, Wheatley, additional, Hryhoriy, Adamchuk, additional, Oleksandr, Berzoy, additional, Igor, Bondarenko, additional, Oleksii, Kolesnik, additional, Olena, Kolesnik, additional, Hanna, Komisarenko, additional, Anna, Kryzhanivska, additional, Iurii, Leshchenko, additional, Alla, Nasonova, additional, Natalya, Otchenash, additional, Olga, Ponomarova, additional, Andrii, Rusyn, additional, Sergii, Shevnya, additional, Yaroslav, Shparyk, additional, Dmytro, Trukhin, additional, Grygorii, Ursol, additional, Ihor, Vynnychenko, additional, Sibel, Blau, additional, Madhu, Chaudhry, additional, Michael, Chung, additional, Patrick, Cobb, additional, Scott, Cole, additional, Jennifer, Diamond, additional, Keerthi, Gogineni, additional, Jeffrey, Hargis, additional, Kent, Hoskins, additional, William, Irvin, additional, Randa, Loutfi, additional, Janice, Lu, additional, Raul, Mena, additional, Susan, Moore, additional, Rita, Nanda, additional, Ira, Oliff, additional, Coral, Omene, additional, Timothy, Panella, additional, Amit, Panwalkar, additional, Brian, Patson, additional, Hope, Rugo, additional, Irina, Rybalova, additional, Michael, Schleider, additional, Robert, Siegel, additional, Michael, Simon, additional, Laura, Stampleman, additional, Bradley, Sumrall, additional, Michaela, Tsai, additional, and Frances, Valdes-Albini, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results